// App-Quantinova.ai

7553 : A phase II prospective clinical study of the sandwich protocol, VDLP combined with concurrent radiation and cisplatin in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.

Researchers

Presenter

  • Li Zhang

Principal Investigators

  • Ming Jiang

  • Li Xie

  • Hong Zhang

  • Yu Jiang

  • Weiping Liu

  • Wenyan Zhang

  • Rong Tian

  • Yaotiao Deng

  • Sha Zhao

  • Liqun Zou

Medical Centers

  • The Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China

  • Radiation Oncology of Cancer Center, West China Hospital, Chengdu, China

  • Pathology Department, West China Hospital, Chengdu, China

  • Department of Nuclear Medicine, West China Hospital, Chengdu, China

  • The Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • T-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Asparaginase

  • Etoposide

  • Etoposide phosphate

  • Cisplatin

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved